Press Coverage 

"Social Medwork sees its network as filling a gap in the market for the latest drugs against diseases such as cancer, migraine and multiple sclerosis. In the past 18 months, the group has supplied more than 3,000 patients. The Dutch group, which charges a fee of around 6 percent, claims to be the only organization focused on newly approved branded drugs."

Read more...

Publication: CNBC
Date: 3 October 2018
Country: Global